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Introduction
Worldwide, acute lung injury (ALI) and acute respiratory 
distress syndrome (ARDS) are associated with a high 
mortality rate (35 to 45%) [1]. Modern ventilation strate-
gies include the use of low tidal volumes and/or limiting 
plateau pressure and have been shown to reduce 
morbidity and mortality in patients with ALI and ARDS 
[2-4]. Th   e subsequent increase in arterial carbon dioxide 
tension (PaCO2) is regarded as an acceptable side-eﬀ  ect 
(‘permissive hypercapnia’). In current practice, mean 
maximum PaCO2 and pH associated with permissive 
hypercapnia are around 8.9 kPa and 7.2, respectively [2], 
and are reported to be well tolerated as long as tissue 
perfusion and oxygenation are preserved and there are 
no contraindications [5-7]. Numerous studies have 
investi  gated the eﬀ  ects of hypercapnic acidosis (HCA) in 
laboratory animals and humans; to date, however, it is 
unclear whether HCA should be considered as an accep-
table adverse eﬀ  ect of lung-protective ventilation or as 
therapeutic by itself (‘therapeutic hypercapnia’). Human 
trials studying the eﬀ  ect of carbon dioxide (CO2) per se
on outcome in patients with lung injury have not been 
carried out to date. After brieﬂ  y summarizing the physio-
logical eﬀ  ects of HCA, we present a critical analysis of 
the available evidence on the potential beneﬁ  cial eﬀ  ects 
of therapeutic HCA from in vitro, ex vivo and in vivo lung 
injury models and from human studies.
Physiological eff  ects of hypercapnic acidosis
HCA has a myriad of eﬀ   ects on many physiological 
processes. Th  e recognition of these eﬀ  ects is important 
as it will aﬀ  ect the decision whether or not to allow the 
development of HCA in a speciﬁ  c patient. As outlined 
below, the ﬁ  nal eﬀ  ect of HCA on physiological functions 
depends on the level of hypercapnia, the context of the 
subject (healthy versus diseased) and many other factors. 
Th   erefore, we will brieﬂ  y review the physiological eﬀ  ects 
of HCA.
Oxygenation
Th  e beneﬁ  cial eﬀ  ects of HCA in increasing arterial and 
tissue oxygenation is evident from multiple in vivo
studies [8-16] and has been demonstrated in healthy 
humans as well [17]. HCA can improve tissue oxyge-
nation by several mechanisms. First, a rightward shift of 
the oxyhemoglobin dissociation curve during acute 
respiratory acidosis decreases the aﬃ   nity of hemoglobin 
for oxygen and facilitates oxygen release to the tissues 
(the Bohr eﬀ  ect) [18]. Second, HCA causes vasodilatation 
in microvessels, promoting oxygen delivery and tissue 
perfusion. However, high concentrations of PCO2
(>13.3 kPa) will surpass the beneﬁ  cial vasodilatory eﬀ  ects 
of HCA and result in vasoconstriction [19]. Th  ird,  HCA 
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© 2010 BioMed Central Ltdimproves ventilation-perfusion (V/Q) matching by 
poten  tiat  ing hypoxic pulmonary vasoconstriction [15,16]. 
In contrast, impaired V/Q matching has been demon-
strated with HCA in patients with ARDS [20,21]. Th  e 
diﬀ  erences in V/Q matching in these studies could be 
explained by the manner in which hypercapnia was 
achieved - inhaled CO2 [15,16] versus low-volume 
(pressure-limited) ventilation-induced hypercapnia. In 
the latter case, atelectasis may develop, leading to 
increased intrapulmonary shunting [20,21]. As inhaled 
CO2 theoretically results in a more uniform lung acidosis, 
it might be superior to low minute ventilation-induced 
hypercapnia in achieving improved V/Q matching and an 
anti-inﬂ  ammatory  eﬀ   ect, as has been suggested by 
Sinclair and colleagues [22]. Fourth, as cardiac output is 
one of the major determinants of peripheral oxygen 
delivery, one can expect that a CO2-mediated increase in 
cardiac output augments peripheral oxygen delivery. 
However, an increase in cardiac output results in an 
increase in mixed venous oxygen tension which may lead 
to an increase in pulmonary shunting due to attenuation 
of hypoxic pulmonary vasoconstriction [21,23].
The lung
Pulmonary compliance
As will be outlined below, it has been demonstrated in 
experimental studies that pulmonary compliance is 
improved by HCA. Th  is may be explained by the pH-
mediated eﬀ   ect of HCA in improving surfactant 
secretion and its surface-tension-lowering properties 
[24,25].
Pulmonary vascular tone
Increases in pulmonary vascular tone may have 
particularly unfavorable consequences in patients with 
pulmonary hypertension. Experimental evidence is 
conﬂ   ict  ing concerning the pulmonary vasodilatory or 
vasoconstrictive eﬀ  ect of HCA [9,26-30]. Th  ese  apparent 
opposing eﬀ  ects may be attributable to the presence or 
absence of pH-buﬀ  er resulting in pulmonary vasodila-
tation or vasoconstriction, respectively [26,29,30].
However, clinical studies demonstrate that HCA causes 
an increase in mean pulmonary arterial pressure in 
ARDS [5,31]. Recently, Mekontso and colleagues [32] 
showed a lower right ventricular stroke index in patients 
with severe ARDS who were ventilated with higher 
positive end-expiratory pressure (PEEP; 10 to 11 mmHg) 
at a constant plateau pressure that subsequently led to 
HCA (pH 7.17 to 7.20, PaCO2 9.44 to 9.98 kPa). An 
increase in pulmonary vascular resistance was postulated 
but no objective measurements were performed. 
Multivariate analysis demonstrated that pH, per se, and 
not CO2 or PEEP, was responsible for the impaired right 
ventricular function [32]. Th   erefore, caution is warranted 
with the use of ‘permissive’ or ‘therapeutic’ HCA in 




HCA has a direct suppressive eﬀ   ect on cardiac 
contractility, but it can lead to a net increase in cardiac 
output by several mechanisms, as has been demonstrated 
in both animal and human studies [15,17,19,31,33-35]. 
First, sympathetically mediated release of catecholamines 
due to neuroadrenal stimulation results in an increase in 
end-systolic volume and venous return [34,35]. In 
addition to an increase in heart rate, HCA induces ATP-
sensitive K+ channel-mediated vasodilation, as has been 
demonstrated for the brain vasculature and coronary 
vessels [36,37], which could decreases left ventricular 
afterload. An increase of 1.33 to 1.60 kPa in PaCO2 
increases cardiac index by 14% in the critically ill and 
healthy mechanically ventilated patient [17,33]. In the 
clinical setting, however, care should be taken with 
patients exhibiting depressed myocardial function.
Myocardium
Acidosis has protective eﬀ   ects against myocardial 
ischemia-reperfusion injury [38,39]. Hydrogen ions 
inhibit Ca2+ inﬂ   ux into the myocardial ﬁ  ber,  which 
decreases myocardial contractility and oxygen demand, 
leading to less tissue injury during myocardial ischemia 
[39-41]. Furthermore, hypercapnia causes coronary 
vasodilatation, which may be of further beneﬁ  t during 
the period of reperfusion [40]. Th   ese protective eﬀ  ects of 
hypercapnia can be of pivotal importance in the 
treatment of patients undergoing coronary artery bypass 
grafting with extracorporeal circulation and subsequently 
experiencing myocardial suppression.
Central nervous system
Cerebral blood fl  ow and tissue oxygenation
In the absence of intracranial hypertension, HCA may 
have beneﬁ  cial  eﬀ  ects on the brain. Hypercapnia may 
improve cerebral blood ﬂ   ow by decreasing cerebro-
vascular resistance through dilatation of arterioles and 
improves tissue oxygenation, as has been demonstrated 
in both human and animal studies [13,42-44]. Conse-
quently, HCA has protective eﬀ   ects against cerebral 
hypoxic-ischemic injury, as has been demonstrated in rat 
models [45,46]. In a recent clinical study, it was shown 
that cerebral perfusion changed by 4.0 ml/100 g/minute 
for each 0.133 kPa change in the partial pressure of CO2 
(pCO2) [44].
Hypercapnia results in cerebral vasodilatation and a 
subsequent rise in cerebral blood ﬂ  ow. In the presence of 
disturbed auto-regulation this can cause critical 
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perfusion (reviewed in [6]). Th  erefore, HCA should be 
avoided in cases of intracranial pathology, in particular in 
the absence of intracranial pressure recording.




Alveolar macrophages play a prominent role in the 
pathogenesis of ventilator-induced lung injury (VILI), 
possibly through the generation of cytokines, chemo-
kines, nitric oxide (NO) and free radicals [47-49]. Upon 
stimulation, alveolar macrophages release proinﬂ  amma-
tory cytokines and chemokines, resulting in the activa-
tion of polymorphonuclear leucocytes (reviewed in [50]). 
Activated polymorphonuclear leucocytes increase endo-
thelial and epithelial permeability, resulting in tissue edema 
and accumulation of high-molecular-weight proteins in the 
airspaces (reviewed in [50]). HCA decreases cytokine 
release by alveolar macrophages and this eﬀ  ect appears 
to be primarily pH-mediated [51,52]. For instance, Lang 
and colleagues [53] demonstrated that CO2 decreased 
lipopolysaccharide (LPS)-induced TNF-α secretion in rat 
alveolar macrophages in a dose-dependent fashion. Four 
hours after exposure to 20% CO2 (pH 5.8), TNF-α 
secretion was only 50% compared to cells exposed to 
2.5% CO2  (pH 7.2). However, buﬀ   ering the culture 
medium pH to 7.2 completely abolished the eﬀ  ect  of 
hyper  capnia. A decrease in cell metabolic activity 
appeared to be responsible for the pH-induced decline in 
cytokine release in these cells as incubation with 20% 
CO2  resulted in an approximately 40% reduction in 
metabolic activity and an equal reduction in LPS-
stimulated TNF-α secretion [54].
Alveolar type II epithelial cells
Hypercapnia has detrimental eﬀ  ects on alveolar type II 
epithelial cells. For example, in buﬀ  ered fetal rat type II 
alveolar epithelial cells, injury is caused by a hypercapnia-
mediated increase in NO, NO synthase and 3-nitro-
tyrosine leading to protein tyrosine nitration [55]. 
Additionally, in a scratch injury model where primary 
type II rat alveolar epithelial cells were injured with a 
surgical blade, HCA caused more permanent plasma 
membrane defects and an impaired rate of plasma 
membrane repair [56]. Recently, O’Toole and colleagues 
[57] reported impaired pulmonary epithelial wound 
healing by HCA-induced diminished cellular migration 
through inhibition of NF-κB. NF-κB is a transcription 
factor responsible for the transcription of intercellular 
adhesion molecule (ICAM)-1 and pro-inﬂ  ammatory 
cytokines such as TNF-α, IL-1β, IL-6 and IL-8 (reviewed 
in [58,59]). NF-κB is present in the cytoplasm in an 
inactive form through its interaction with inhibitory 
proteins κB (IκB) and can be activated by multiple 
stimuli.  Regarding the potential for HCA to delay 
pulmonary epithelial wound repair following mechanical 
injury, these studies raise concerns regarding epithelial 
repair in patients with ALI/ARDS undergoing 
‘permissive’ hypercapnia.
Pulmonary artery endothelial cells
HCA has been demonstrated to inhibit NF-κB in pulmo-
nary artery endothelial cells [60]. In isolated human 
pulmonary artery endothelial cells, Takeshita and 
colleagues [60] demonstrated that HCA suppressed IκB 
degradation, resulting in reduced NF-κB activity. Th  is 
resulted in decreased expression of ICAM-1 and IL-8 
with subsequent inhibition of neutrophil adherence 
(Figure 1). As inﬂ  ammation plays an important role in 
the pathogenesis of VILI, this modulating eﬀ  ect of HCA 
on the inﬂ  ammatory response may further reduce lung 
injury during mechanical ventilation associated with 
hyper capnia.
Experiments in ex vivo lung preparations
In isolated perfused rabbit lungs it has been demon-
strated that HCA (pH 6.84, PCO2 15.96 kPa) prevents the 
development of microvascular permeability by warm 
ischemia-reperfusion and free-radical-mediated lung 
injury, possibly via inhibition of endogenous xanthine 
oxidase [61]. Also, less severe levels of HCA have been 
shown to attenuate ischemia-reperfusion injury in the 
isolated rabbit lung [26].
Xanthine oxidase is involved in the metabolism of 
purines and pyrimidines and generates superoxide and 
subsequently hydrogen peroxide when oxidizing 
hypoxanthine or xanthine to uric acid [62]. As various 
studies have demonstrated a possible role for reactive 
oxygen species (ROS) in the pathogenesis of ARDS, HCA 
may oﬀ  er protection against ROS-mediated lung injury 
by inhibiting xanthine oxidase [63,64].
Broccard and colleagues [65] have demonstrated a 
protective role of HCA against reactive nitrogen species 
(RNS)-mediated lung injury by attenuating the rise in 
stable end-products of NO metabolism. However, the 
eﬀ   ects of HCA on RNS are complex. In addition to 
reducing RNS-mediated injury, HCA can enhance tissue 
nitration. Th   is has been demonstrated by increased lung 
nitrotyrosine levels in animals treated with HCA follow-
ing endotoxin injury and in animals subjected to VILI 
[10,66]. It appears that the net eﬀ  ect of HCA on nitrogen 
radicals may be beneﬁ  cial, perhaps because the oxidant 
pathway is more injurious. More studies are, however, 
necessary to clearly demonstrate this.
Both ROS and RNS are generated in response to 
various inﬂ  ammatory stimuli in lung endothelial, alveolar 
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macrophages and neutrophils [63]. Th  is may result in 
oxidation, nitration and inactivation of important proteins, 
DNA and lipids. For example, peroxynitrite can oxidize 
and nitrate surfactant protein A, resulting in loss of its 
function [67,68]. Alterations in the function, production 
and composition of surfactant stimulates alveolar 
collapse with subsequent loss of compliance and 
deterioration in gas exchange. Impaired surfactant 
function has been reported in patients with ARDS and 
may aggravate respiratory failure (reviewed in [69]). As 
such, HCA may oﬀ  er protection against lung injury by 
preventing surfactant nitration [70,71].
Furthermore, it has been demonstrated that HCA 
increases lamellar body volume density of type II 
pneumocytes in dog lungs. As lamellar body volume 
density of type II pneumocytes is known to be associated 
with intracellular storage and secretion of surfactant, 
HCA may have a stimulating role on surfactant release 
[24]. An indirect eﬀ  ect of HCA on surfactant function 
has also been envisioned. As HCA has been shown to 
diminish pulmonary microvascular permeability 
[26,56,61,70], it will prevent elevated bronchoalveolar 
lavage ﬂ   uid (BALF) protein concentration, which has 
been shown to decrease surfactant activity [72]. In the 
future, in vivo studies are mandatory to investigate the 
Figure 1. Modulating eff  ect of hypercapnic acidosis on the infl  ammatory response. NF-κB can be activated by multiple stimuli, such as 
endotoxin (lipopolysaccharide), reactive oxygen species (ROS) and cytokines (IL-1β and TNF-α). Subsequently, phosphorylation of IκB (inhibitory 
proteins κB) occurs followed by its degradation, allowing NF-κB to be transported to the cell nucleus where it binds to specifi  c promoter sites and 
activates transcription of target genes. Following activation of NF-κB, both intra- and extracellular feedback mechanism will subsequently regulate 
NF-κB activation, with IL-1β and TNF-α providing positive extracellular feedback. The potential mechanism by which hypercapnic acidosis (HCA) 
inhibits NF-κB activation appears to involve suppression of the degradation of IκB-α. Subsequently, this will result in suppressed production of IL-1β, 
IL-6, IL-8 and TNF-α. Suppression of intercellular adhesion molecule (ICAM)-1 and IL-8 will subsequently lead to inhibition of neutrophil adherence. 
HCA may also off  er protection against ROS-mediated lung injury by inhibiting xanthine oxidase (XO).
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lung injury.
In vivo animal studies
HCA may have protective eﬀ  ects against lung injury as 
has been shown in multiple in vivo models of lung injury, 
including ALI induced by bacterial [12,73] or endotoxin 
instillation [10,74], systemic [9] and pulmonary ischemia-
reperfusion [70] and stretch-induced lung injury 
[8,11,75-77], as outlined below.
Bacterial- and endotoxin-induced lung injury
In an established Escherichia coli-induced lung injury 
model, CO2 was added 6 hours after E. coli instillation, 
allowing the development of severe pneu  monia. Inspired 
CO2 attenuated the fall in arterial oxygenation, the 
increase in peak airway pressure and the reduction in 
lung compliance. Moreover, histologic lung injury was 
reduced in the hypercapnic group compared to the 
normocapnic group in the presence of antibiotic therapy 
[73]. However, no diﬀ  erences in bacterial loads, BALF 
neutrophil counts, IL-6 or TNF-α levels were found. 
Th   ese results were conﬁ  rmed by the same investi  gators in 
the setting of evolving pneumonia-induced lung injury 
[12]. In this study, CO2 was added immediately after 
E. coli instillation in both neutrophil-depleted and non-
depleted rats, suggesting a neutrophil-independent 
mechanism for the eﬀ  ect of HCA [12].
HCA attenuated endotoxin-induced lung injury in rats 
as shown by improved arterial oxygenation, reduced 
alveolar inﬂ  ux of neutrophils and alveolar/tissue edema, 
reduced NO metabolite concentrations, improved lung 
compliance and improved histological indices of lung 
injury when given both prophylactically (before endo-
toxin instillation) as well as therapeutically (30 minutes 
after endotoxin instillation) [10]. As ALI is generally well 
established before the patient comes to the ICU, these 
data emphasize the potential clinical relevance of HCA. 
In contrast to these results, an increase in alveolar-
capillary membrane permeability, lung wet-to-dry ratio, 
BALF cell counts, indices of oxidative inﬂ  ammatory 
reactions and lung histologic injury were observed with 
hypercapnia in an intravenous endotoxin-induced ALI 
rabbit model [74]. Possible explanations for the apparent 
discrepancies may be diﬀ  erences in plasma CO2 tension 
(±9.7 kPa versus ±7.8 kPa), species used (rat versus 
rabbit), route of LPS administration (intratracheal versus 
intravenous) and the method of producing HCA (inhaled 
CO2 versus low minute ventilation-induced hypercapnia) 
[10,74].
Ischemia-reperfusion lung injury
Pulmonary ischemia-reperfusion injury may occur in 
humans after, for instance, cardiopulmonary bypass, 
thrombolysis or embolectomy for pulmonary embolism 
and lung transplantation. In an open chest rabbit model 
of lung ischemia-reperfusion injury, therapeutic HCA 
has been demonstrated to exert beneﬁ  cial  eﬀ  ects. 
Attenuation of the inﬂ  ammatory response was demon-
strated by reduced TNF-α concentration and free-
radical-mediated injury [70]. Th   ese data are supported by 
the dose-dependent beneﬁ  cial  eﬀ   ects of HCA on 
mesenteric ischemia-reperfusion-induced lung injury [9].
Stretch-induced lung injury
Mechanical ventilation with high tidal volumes or high 
peak pressure and/or low PEEP causes excessive lung 
stretch and shear forces, which are considered key deter-
minants of VILI [78,79].
Increased lung compliance, higher arterial partial 
pressure of oxygen (PaO2) and a decrease in lung injury 
have been demonstrated with HCA in a rabbit VILI 
model [11]. Stretch-induced lung injury was achieved by 
subjecting the rabbits to extremely high tidal volume 
ventilation (25 ml/kg) and zero PEEP. Although this study 
suggested that the eﬀ  ect of HCA was independent of 
tidal volume, it is of limited clinical relevance as both 
groups were ventilated with these high tidal volumes. 
However, HCA has demonstrated protective eﬀ  ects at 
more clinically relevant tidal volumes [8,75], though 
these eﬀ   ects were less impressive. Th  is supports the 
theory that lung-protective ventilation strategies reduce 
VILI to a point that a protective eﬀ  ect of HCA is less 
detectable.
Recently, we studied the eﬀ  ect of HCA on the immune 
response by adding CO2 to the inspiratory mixture in a 
mild VILI model in mice. Indeed, HCA decreased intra-
pulmonary cytokine levels, leucocyte inﬂ  ux and wet-dry 
ratio in a dose-dependent fashion [76,80] (Figure 2). 
Th   ese results are in apparent contrast with the ﬁ  ndings of 
a previous study performed in a surfactant-depleted 
rabbit model [77]. Despite attenuation of BALF monocyte 
chemoattractant protein-1, no eﬀ  ect of HCA was found 
on other inﬂ  ammatory mediators, vascular permeability, 
lung mechanics or oxygenation. However, an inhaled CO2 
concentration of 12% was used, resulting in extremely 
high values of PaCO2 (>18.6 kPa) and very low pH (<6.9), 
which may have inﬂ  uenced these results. Additionally, as 
the authors mentioned, the model is prone to atelectasis 
and HCA may, therefore, be less eﬀ  ective in attenuating 
lung injury. Furthermore, HCA may improve surfactant 
production and decrease surfactant surface tension. In 
this surfactant-depleted rabbit model these beneﬁ  cial 
eﬀ  ects of HCA will therefore be absent [24,25].
Human data
Th   e ARDSnet trial showed that tidal volume ventilation 
using 6 ml/kg ideal body weight in patients suﬀ  ering 
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mortality of 8.8% compared to the use of tidal volumes of 
12 ml/kg [3]. Although the PaCO2 was slightly higher in 
the low tidal volume arm, the eﬀ  ects of HCA could not 
be separated from lung protective ventilation as an 
explanation for the decrease in mortality. However, a 
secondary analysis, using multivariate logistic regression 
and controlling for co-morbidities and severity of lung 
injury, demonstrated that HCA on day 1 (pH <7.35, 
PaCO2 >6 kPa) was associated with reduced mortality in 
patients ventilated with 12 ml/kg but not in patients 
ventilated with 6 ml/kg [81]. A dose-response relation-
ship between HCA and mortality in this group was 
demonstrated.
Recently, Terragni and colleagues [82] showed a 
reduction of tidal hyperinﬂ  ation and an attenuation of 
pulmonary inﬂ   ammation during ventilation with low 
tidal volumes of 4.2 ± 0.3 ml/kg compared to tidal 
volumes of 6.3 ± 0.3 ml/kg. Th  e development of HCA 
was eﬀ  ectively and safely managed by extracorporeal CO2 
removal. Th  e question remains if morpho  logical and 
inﬂ   ammatory parameters would even be further 
improved without the use of extracorporeal CO2 removal. 
To date, however, human trials studying the eﬀ  ect of CO2 
per se on outcome in patients with lung injury have not 
been performed.
In conclusion, based on the experimental data, HCA 
may have direct protective eﬀ  ects against lung injury as 
described above. Potential mechanisms responsible for 
this beneﬁ  cial  eﬀ   ect are complex and probably 
multi  factorial and may be diﬀ   erent depending on the 
cause of lung injury. At least a reduction in inﬂ  ammatory 
mediators via the NF-ĸB pathway, a reduction in RNS 
and ROS via inhibiting xanthine oxidase and an 
improvement in surfactant function appear to play an 
important role in the prevention of lung injury by HCA.
Hypercapnic acidocis versus hypercapnia
Th   e protective eﬀ  ects of HCA in lung injury models may 
be a function of pH or the CO2 per se. Th  is issue is of 
signiﬁ   cant relevance when considering the need for 
buﬀ  ering HCA in the clinical context.
Th  e protective eﬀ  ect of HCA in experimental studies 
(cell culture studies [55], ex vivo studies [26] as well as in 
in vivo studies [83]) demonstrate that pH buﬀ  ering of 
HCA attenuates its lung protective eﬀ  ect. Th  is suggests 
that the protective eﬀ  ect of HCA appears to be a function 
of pH, rather than elevated CO2  per se. However, a 
synergistic eﬀ  ect between CO2 and pH may exist, as HCA 
seems to be more protective than metabolic acidosis in 
the setting of ALI [26].
Besides the relevance of the type of acidosis (hyper-
capnic versus metabolic), the type of buﬀ  er  (sodium 
bicarbonate versus tris-hydroxymethyl aminomethane 
(THAM)) seems to be of particular importance. Despite 
correcting the arterial pH, administration of sodium 
bicarbonate has the disadvantage that it may worsen 
intracellular acidosis. Th  e  CO2 generated diﬀ  uses rapidly 
across cell membranes to equilibrate between intra-
cellular and extracellular compartments, leading to 
intracellular acidosis [84].
Since no human trials have been performed to 
investigate the eﬀ   ect of buﬀ   ering during the use of 
‘therapeutic hypercapnia’, no advise about buﬀ  ering at the 
bedside can be given.
Other evidence of harm with hypercapnic acidosis
Host response to infections
HCA may attenuate lung injury by reducing neutrophil 
activity, concentrations of key cytokines, such as TNF-α, 
IL-1β, IL-6 and IL-8, and the expression of ICAM-1 
[10,12,51,52,54,60,70,76,85]. However, the phagocytic 
activity and bactericidal capacity of neutrophils and 
macrophages are essential for an eﬀ  ective host response 
to invading bacteria. As one of the most common causes 
of ALI/ARDS remains sepsis [86], concerns have been 
expressed about the possible deleterious eﬀ  ects of HCA 
on bacterial killing [87,88]. Recently, Costello and 
colleagues [89] reported a beneﬁ  cial eﬀ  ect of HCA in 
reducing the severity of lung injury in early and 
prolonged systemic sepsis. Additionally, no eﬀ  ect of HCA 
on bacterial load was demonstrated, providing some 
reassurance regarding the safety of HCA in the clinical 
setting of sepsis.
Figure 2. Eff  ect of hypercapnic acidosis on lung tissue cytokines 
in ventilated mice. Eff  ect of 2 hours of normo- and hypercapnic 
mechanical ventilation on ventilation-induced lung tissue cytokine 
release using identical ventilator settings. *P < 0.05 versus control; 
+P < 0.05, 0.06% CO2 versus 2% CO2 versus 4% CO2. KC, keratinocyte-
derived chemokine. This fi  gure is reproduced with permission of the 
publisher. (Halbertsma FJ, Vaneker M, Pickkers P, et al. Hypercapnic 
acidosis attenuates the pulmonary innate immune response in 
ventilated healthy mice. Crit Care Med 2008, 36:2403-2406.).
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Various studies have demonstrated an acidosis-mediated 
suppressant eﬀ  ect on the phagocytic activity of neutro-
phils and macrophages [90] (reviewed in [91]). Recently, 
it has been demonstrated that sustained HCA in the 
presence of prolonged pulmonary infection without 
antibiotic therapy increases bacterial load and worsens 
lung injury, mainly through inhibition of neutrophil 
phagocytosis. However, no diﬀ   erence in lung damage 
between the normocapnic and HCA group was found 
with co-administration of antibiotics [92]. Th  is  unfavor-
able eﬀ  ect of HCA is in contrast with other in vivo studies 
reporting no diﬀ  erence [93] or a modest protective eﬀ  ect 
of HCA in evolving and established pneumonia-induced 
lung injury [12,73]. It is also in contrast with the 
beneﬁ  cial  eﬀ   ects of HCA in the setting of early and 
prolonged systemic sepsis. Th   is suggests that the eﬀ  ects 
of HCA appear to depend on the site of infection as well 
as the stage of infection.
Reduced neutrophil respiratory burst
An acidosis-mediated suppressant eﬀ  ect on intracellular 
killing by reduced production of ROS by macrophages 
and neutrophils has also been demonstrated [90,94] 
(reviewed in [91]). In human neutrophils, HCA was 
associated with a pH-dependent decrease in intracellular 
oxidant production and IL-8 secretion [85].
Neuromuscular system
Prolonged hypercapnia may have negative eﬀ  ects on the 
neuromuscular function of the diaphragm. Degenerative 
changes of the diaphragm were observed after keeping 
rats in hypercapnic chambers for 6 weeks or more 
[95,96]. Th  ese data are of particular importance in the 
clinical context, where neuromuscular function of the 
diaphragm plays a pivotal role in the success of weaning 
from the ventilator.
Milieu interne
HCA decreases hyperlactatemia in the context of global 
hypoxemia as well as during normoxia [15,70,97]. 
Prevention of hyperlactatemia is probably due to a pH-
mediated suppressive eﬀ   ect of HCA on lactic acid 
generation by decreasing cell metabolism through 
inhibition of glycolysis (reviewed in [98]). Subsequently, 
this leads to diminished cellular fuel utilization in times 
of ischemia. It is reasonable to think that a cellular 
metabolic shutdown can be beneﬁ  cial for, for example, 
the kidney, but it may have unfavorable eﬀ  ects for the 
brain
Clinical perspective and recommendations
Th  e protective eﬀ   ect of ‘therapeutic’ HCA has been 
demonstrated in various lung injury models [9,10,12, 
70,73,74]. However, caution should be taken when extra-
polating these results to the clinical setting. Importantly, 
the studies performed use diﬀ  erent models (that is, levels 
of hypercapnia, duration and timing of hypercapnia, 
healthy or injured lungs), with diﬀ  erent and sometimes 
conﬂ   icting outcomes that make comparison diﬃ   cult. 
Accordingly, the optimal CO2 level for mechanically 
ventilated patients with ALI is unknown. Th   e concept of 
an optimal CO2 concentration is essential as most 
physiological systems are saturable and it is therefore 
reasonable that an eﬀ  ective upper limit of CO2, a point 
beyond which advantages shift towards harmful eﬀ  ects, 
exists.
Despite these uncertainties, the potential for thera-
peutic hypercapnia in attenuating lung injury is 
promising. Th  is review supports the need for studying 
thera  peutic HCA at the bedside in patients without 
contraindications in a pilot setting. Diﬀ  erent methods of 
eliciting hypercapnia (inhaled CO2 versus low minute 
ventilation-induced hypercapnia) need further investiga-
tion, especially in human studies
Conclusion
Modern ventilation strategies have demonstrated a 
reduction in mortality in patients with ALI and ARDS. 
Th  e subsequent HCA is regarded as an acceptable side 
eﬀ   ect and is generally well tolerated. Experimental 
studies have reported a myriad of eﬀ  ects of HCA on 
many physiological processes. Despite the fact that 
concerns remain regarding HCA, in particular impaired 
bacterial killing and the inhibition of pulmonary 
epithelial wound repair, the potential for therapeutic 
HCA in attenuating lung injury is promising.
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